• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography.

作者信息

Benedetti Edoardo, Baratè Claudia, Bruno Benedetto, Bramanti Emilia, Ghia Paolo, Scarfò Lydia, Morganti Riccardo, Ricchiuto Vittorio, Galimberti Sara

机构信息

Azienda Ospedaliero-Universitaria Pisana, Department of Clinical and Experimental Medicine, UO Hematology, University of Pisa, Italy.

Department of Molecular Biotechnology and Health Sciences, University of Turin, Italy.

出版信息

Leuk Res. 2021 Jan;100:106488. doi: 10.1016/j.leukres.2020.106488. Epub 2020 Nov 30.

DOI:10.1016/j.leukres.2020.106488
PMID:33316660
Abstract
摘要

相似文献

1
Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography.超声检查对复发/难治性慢性淋巴细胞白血病患者维奈克拉治疗的反应评估
Leuk Res. 2021 Jan;100:106488. doi: 10.1016/j.leukres.2020.106488. Epub 2020 Nov 30.
2
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Venetoclax 治疗伴有 17p 缺失的复发或难治性慢性淋巴细胞白血病：一项多中心、开放标签、2 期研究。
Lancet Oncol. 2016 Jun;17(6):768-778. doi: 10.1016/S1470-2045(16)30019-5. Epub 2016 May 10.
3
Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement.维奈克拉可穿透脑脊液，对合并中枢神经系统受累的慢性淋巴细胞白血病可能有效。
Haematologica. 2019 May;104(5):e222-e223. doi: 10.3324/haematol.2018.213157. Epub 2019 Feb 14.
4
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia.维奈托克和伊布替尼用于复发/难治性慢性淋巴细胞白血病患者。
Blood. 2021 Feb 25;137(8):1117-1120. doi: 10.1182/blood.2020008608.
5
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.维奈托克联合利妥昔单抗治疗复发或难治性慢性淋巴细胞白血病：一项1b期研究
Lancet Oncol. 2017 Feb;18(2):230-240. doi: 10.1016/S1470-2045(17)30012-8. Epub 2017 Jan 13.
6
Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia.维奈托克治疗既往治疗的慢性淋巴细胞白血病患者。
Clin Cancer Res. 2017 Aug 15;23(16):4527-4533. doi: 10.1158/1078-0432.CCR-16-0955. Epub 2017 Jan 18.
7
The impact of anti-bacterial prophylaxis on the outcome of patients treated with venetoclax-based regimens for relapsed/refractory plasma cell dyscrasias: Real-life data.抗菌预防对接受基于维奈克拉方案治疗的复发/难治性浆细胞异常患者结局的影响：真实世界数据。
Leuk Res. 2020 Oct;97:106429. doi: 10.1016/j.leukres.2020.106429. Epub 2020 Jul 30.
8
Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.美国接受维奈托克治疗的慢性淋巴细胞白血病患者的真实世界结局和管理策略。
Haematologica. 2018 Sep;103(9):1511-1517. doi: 10.3324/haematol.2018.193615. Epub 2018 Jun 7.
9
Potential of BCL2 as a target for chronic lymphocytic leukemia treatment.BCL2作为慢性淋巴细胞白血病治疗靶点的潜力。
Expert Rev Hematol. 2018 May;11(5):391-402. doi: 10.1080/17474086.2018.1456332. Epub 2018 Mar 29.
10
How I manage CLL with venetoclax-based treatments.基于 venetoclax 的治疗方案治疗 CLL 的体会
Blood. 2020 Apr 23;135(17):1421-1427. doi: 10.1182/blood.2019002841.

引用本文的文献

1
Real-life diagnostic and therapeutic approach to CLL: a 2022 update from an expert panel in Tuscany.真实世界中 CLL 的诊断和治疗方法：来自托斯卡纳专家小组的 2022 年更新。
Clin Exp Med. 2023 Dec;23(8):4251-4264. doi: 10.1007/s10238-023-01244-5. Epub 2023 Nov 18.
2
Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Treated with Fixed Duration Venetoclax-Rituximab: Assessment of Response with Ultrasound, and Relationship with Minimal Residual Disease.接受固定疗程维奈托克联合利妥昔单抗治疗的复发/难治性慢性淋巴细胞白血病患者：超声评估反应及与微小残留病的关系
J Clin Med. 2023 Feb 23;12(5):1772. doi: 10.3390/jcm12051772.
3
A Prospective Cross-Sectional Study on the Comparison of Ultrasound Assessment vs. Palpation in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy.
一项关于靶向治疗时代慢性淋巴细胞白血病患者超声评估与触诊比较的前瞻性横断面研究。
J Clin Med. 2022 Jun 4;11(11):3206. doi: 10.3390/jcm11113206.